Return to homepagePandemic Pact

Developing a universal direct acting antiviral nasal spray against multiple respiratory viruses

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA352194

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2024
    2028

  • Known Financial Commitments (USD)

    $1,061,791.88

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia, Denmark

  • Lead Research Institution

    Queensland University of Technology

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

We have developed a cheap and rapidly deployable direct acting nose spray that can destroy respiratory viruses replicating in the lungs of mice. Here, we want to further develop our therapy into a universal self-use nasal spray medicine that targets COVID-19 and other common cold viruses in both the lungs and the nose. This universal antiviral nasal spray will be the first of its kind as it will not only reduce respiratory viral illness, but also virus spread and transmission.